Targeted Therapy of Antibody-Induced Autoimmune Arthritis Using Peptide-Guided Nanoparticles.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Rheumatology

Background:

• Rheumatoid arthritis (RA) affects millions globally, with many patients unresponsive to current treatments or experiencing side effects.
• Existing RA therapies often lack joint specificity, leading to systemic exposure and limited efficacy.
• There is a critical need for advanced drug delivery systems to target inflamed joints in RA.

Purpose of the Study:

• To develop and validate a peptide-targeted liposomal drug delivery system for enhanced rheumatoid arthritis therapy.
• To assess the efficacy and joint-homing capabilities of a novel peptide (ART-2) functionalized liposomal dexamethasone (Dex).
• To confirm the therapeutic potential of this nanotechnology in distinct preclinical RA models.

Main Methods:

• Development of ART-2 peptide-functionalized liposomes encapsulating dexamethasone (Dex).
• Evaluation in rat adjuvant-induced arthritis (AA) and mouse collagen antibody-induced arthritis (CAIA) models.
• In vivo live imaging for liposome biodistribution and immunohistochemistry for ART-2 binding and drug delivery.

Main Results:

• ART-2 liposomes demonstrated preferential accumulation in arthritic joints compared to healthy joints.
• Liposomal dexamethasone (Dex) showed superior efficacy in suppressing arthritis compared to free Dex in both AA and CAIA models.
• Immunohistochemistry confirmed ART-2 binding to joint tissues and effective delivery of Dex.

Conclusions:

• Peptide-targeted liposomes represent a promising nanotechnology for effective, joint-specific drug delivery in rheumatoid arthritis.
• The ART-2 liposomal system offers a validated, potentially translatable therapeutic strategy for RA patients.
• This approach may overcome limitations of current RA treatments by improving drug targeting and reducing systemic side effects.